The Food and Drug Administration (FDA) has granted accelerated approval to sotorasib (Lumakras), the first KRAS-blocking drug to clear the regulatory hurdle. The approval, which covers the use of sotorasib to treat some patients with advanced lung cancer, is based on initial results from a phase 1/2 clinical trial dubbed CodeBreaK 100.
In a small clinical trial, vemurafenib (Zelboraf) and rituximab (Rituxan) helped 85% of participants stay in remission for nearly 3 years. The study involved 30 people with hairy cell leukemia that had come back or had not responded to previous treatment.
A treatment regimen that combines the immunotherapy drug nivolumab (Opdivo) with either another immunotherapy drug or chemotherapy may be a new initial treatment option for people with advanced esophageal cancer, according to results of a large clinical trial.
People with advanced melanoma treated with two immunotherapy drugs—nivolumab (Opdivo) and a new drug called relatlimab—lived longer without their cancer getting worse than those treated only with nivolumab, results from a large clinical trial show.
Clinical Trials Information for Patients and Caregivers
This step-by-step guide is intended to help people who wish to look for a clinical trial on their own. The guide includes questions to ask about clinical trials and points to several sources for clinical trial information.
The National Institutes of Health (NIH) Clinical Trials and You website is a resource for people who want to learn more about clinical trials. This page provides answers to common questions about taking part in a clinical trial.
This phase 1/2 trial will test the addition of stereotactic body radiation therapy (SBRT) to a combination of two experimental immunotherapy drugs for people with inoperable pancreatic cancer. Doctors want to see if adding SBRT to immunotherapy will shrink tumors enough for people to receive surgery.
This phase 1 trial will test the safety of adding the immunotoxin moxetumomab pasudotox (Lumoxiti) to rituximab (Rituxan) for people with relapsed hairy cell leukemia (HCL). Moxetumomab pasudotox is FDA approved for relapsed HCL. And rituximab is commonly used to treat the disease. Researchers want to see if combining the drugs can fight HCL better.
This trial will evaluate two different screening strategies for non-cancerous pancreatic cysts to determine which works best at detecting early signs of cancer. Doctors want to compare more frequent versus less frequent monitoring to learn which method leads to better results for people with pancreatic cysts.
